Claimed effect · Eloralintide

Does Eloralintide help with body weight?

C
Grade C — weak human evidence1 phase 2b RCT topline (n=367, 48 wk) · effect size: large
Short answerWeak human evidence. 1 phase 2b RCT topline (n=367, 48 wk): enough to be interesting, not enough to count on. Where an effect is seen it is a large effect. Lilly press release, 30 September 2026, presented at the EASD meeting: in adults with obesity or overweight and type 2 diabetes, eloralintide 9 mg with tirzepatide 15 mg produced 23.3% weight loss at 48 weeks against 14.8% on tirzepatide 15 mg alone and 3.0% on placebo; HbA1c fell 2.9, 2.4 and 0.3 points. Eloralintide alone reached 12.3%. Read with care: 367 people across ten groups, an efficacy estimand, and 10.8–27.0% of the combination groups stopped for adverse events against 2.9% on tirzepatide alone. Not peer-reviewed.

What the studies show

Lilly press release, 30 September 2026, presented at the EASD meeting: in adults with obesity or overweight and type 2 diabetes, eloralintide 9 mg with tirzepatide 15 mg produced 23.3% weight loss at 48 weeks against 14.8% on tirzepatide 15 mg alone and 3.0% on placebo; HbA1c fell 2.9, 2.4 and 0.3 points. Eloralintide alone reached 12.3%. Read with care: 367 people across ten groups, an efficacy estimand, and 10.8–27.0% of the combination groups stopped for adverse events against 2.9% on tirzepatide alone. Not peer-reviewed.

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

  1. 1
    Eli Lilly. EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes.Press release, 30 Sep 2026Phase 2b, 367 randomised, 48 weeks, US and Argentina. Efficacy estimand; not peer-reviewed. NCT06603571.

In context

Eloralintide is a once-weekly amylin receptor agonist from Eli Lilly, tested on its own and, more recently, paired with tirzepatide. In a 263-person phase 2 trial published in The Lancet in 2025, the top doses produced about 20% weight loss at 48 weeks against 0.4% on placebo. Nausea was dose-dependent and fatigue was unusually common. Added to tirzepatide in a phase 2b trial reported by press release in September 2026, it took weight loss in people with type 2 diabetes from 14.8% to 23.3% at 48 weeks. Phase 3 trials are running; it is not approved anywhere.

Eloralintide is investigational (phase 3). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Eloralintide proven to help with body weight?
No. The human evidence is weak (1 phase 2b RCT topline (n=367, 48 wk)); LYO grades it C.
What studies are behind the grade?
Lilly press release, 30 September 2026, presented at the EASD meeting: in adults with obesity or overweight and type 2 diabetes, eloralintide 9 mg with tirzepatide 15 mg produced 23.3% weight loss at 48 weeks against 14.8% on tirzepatide 15 mg alone and 3.0% on placebo; HbA1c fell 2.9, 2.4 and 0.3 points. Eloralintide alone reached 12.3%. Read with care: 367 people across ten groups, an efficacy estimand, and 10.8–27.0% of the combination groups stopped for adverse events against 2.9% on tirzepatide alone. Not peer-reviewed.
Is Eloralintide approved for this?
No. Eloralintide is investigational (phase 3); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Eloralintide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →